Journal
TUMOR BIOLOGY
Volume 36, Issue 5, Pages 3325-3336Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1007/s13277-014-2966-x
Keywords
Rhodium (II) citrate; Maghemite nanoparticles; 4T1 breast cancer; Balb/c mice; Toxicological analysis
Categories
Funding
- Brazilian National Council for Technological and Scientific Development (CNPq)
- Foundation to Support Research in the Federal District (FAPDF)
- Coordination for Further Training of Graduate Staff (CAPES)
- CAPES-Rede CON-NANO, NCT-Nanobiotecnologia
- CNANO-UnB
Ask authors/readers for more resources
Breast cancer is one of the most prevalent cancer types among women. The use of magnetic fluids for specific delivery of drugs represents an attractive platform for chemotherapy. In our previous studies, it was demonstrated that maghemite nanoparticles coated with rhodium (II) citrate (Magh-Rh(2)Cit) induced in vitro cytotoxicity and in vivo antitumor activity, followed by intratumoral administration in breast carcinoma cells. In this study, our aim was to follow intravenous treatment to evaluate the systemic antitumor activity and toxicity induced by these formulations in Balb/c mice bearing orthotopic 4T1 breast carcinoma. Female Balb/c mice were evaluated with regard to toxicity of intravenous treatments through analyses of hemogram, serum levels of alanine aminotransferase, iron, and creatinine and liver, kidney, and lung histology. The antitumor activity of rhodium (II) citrate (Rh(2)Cit), Magh-Rh(2)Cit, and maghemite nanoparticles coated with citrate (Magh-Cit), used as control, was evaluated by tumor volume reduction, histology, and morphometric analysis. Magh-Rh(2)Cit and Magh-Cit promoted a significant decrease in tumor area, and no experimental groups presented hematotoxic effects or increased levels of serum ALT and creatinine. This observation was corroborated by the histopathological examination of the liver and kidney of mice. Furthermore, the presence of nanoparticles was verified in lung tissue with no morphological changes, supporting the idea that our nanoformulations did not induce toxicity effects. No studies about the systemic action of rhodium (II) citrate-loaded maghemite nanoparticles have been carried out, making this report a suitable starting point for exploring the therapeutic potential of these compounds in treating breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available